OBJECTIVE: Disease duration and disease activity may be associated with an increased risk of cardiovascular disease (CVD) in rheumatoid arthritis (RA). The objectives of this study were to investigate (1) the relationship between duration of inflammation and the development of CVD in RA patients and (2) the relationship between RA disease activity over time and CVD in patients with RA. METHODS: RA patients with a follow-up of ≥6 months in the Nijmegen early RA cohort without prior CVD were included. Disease activity over time was calculated using the time-averaged 28 joint disease activity score (DAS28) for each patient. Kaplan-Meier survival analysis and Cox proportional hazards regression were used for the analyses. RESULTS: During follow-up of the 855 patients that were included, 154 CV events occurred. The course of hazards over time did not indicate a change in the risk of CVD over the course of RA (disease duration), which is also reflected by the absence of a deflection in the survival curves. The survival distributions did not differ between patients with a disease duration of <10 years or >10 years (Log-rank test: p=0.82). Time-averaged DAS28 was significantly associated with CVD (p=0.002) after correction for confounders. CONCLUSIONS: Disease duration does not appear to independently affect the risk of CVD. The risk of CVD in RA patients was not increased after 10 years of disease duration compared with the first 10 years. Disease activity over time may contribute to the risk of CVD. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVE: Disease duration and disease activity may be associated with an increased risk of cardiovascular disease (CVD) in rheumatoid arthritis (RA). The objectives of this study were to investigate (1) the relationship between duration of inflammation and the development of CVD in RApatients and (2) the relationship between RA disease activity over time and CVD in patients with RA. METHODS:RApatients with a follow-up of ≥6 months in the Nijmegen early RA cohort without prior CVD were included. Disease activity over time was calculated using the time-averaged 28 joint disease activity score (DAS28) for each patient. Kaplan-Meier survival analysis and Cox proportional hazards regression were used for the analyses. RESULTS: During follow-up of the 855 patients that were included, 154 CV events occurred. The course of hazards over time did not indicate a change in the risk of CVD over the course of RA (disease duration), which is also reflected by the absence of a deflection in the survival curves. The survival distributions did not differ between patients with a disease duration of <10 years or >10 years (Log-rank test: p=0.82). Time-averaged DAS28 was significantly associated with CVD (p=0.002) after correction for confounders. CONCLUSIONS: Disease duration does not appear to independently affect the risk of CVD. The risk of CVD in RApatients was not increased after 10 years of disease duration compared with the first 10 years. Disease activity over time may contribute to the risk of CVD. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Elena Myasoedova; Arun Chandran; Birkan Ilhan; Brittny T Major; C John Michet; Eric L Matteson; Cynthia S Crowson Journal: Ann Rheum Dis Date: 2015-01-30 Impact factor: 19.103
Authors: Vital Da Silva Domingues; Ana M Rodrigues; Sara S Dias; Luís Delgado; Ebrahim Barkoudah; Jaime Branco; Helena Canhão Journal: Rheumatol Int Date: 2021-01-03 Impact factor: 2.631
Authors: Bogdan Batko; Karol Urbański; Jerzy Świerkot; Piotr Wiland; Filip Raciborski; Mariusz Jędrzejewski; Mateusz Koziej; Marta Cześnikiewicz-Guzik; Tomasz J Guzik; Marcin Stajszczyk Journal: Clin Rheumatol Date: 2019-05-10 Impact factor: 2.980
Authors: D H Solomon; G W Reed; J M Kremer; J R Curtis; M E Farkouh; L R Harrold; M C Hochberg; P Tsao; J D Greenberg Journal: Arthritis Rheumatol Date: 2015-06 Impact factor: 10.995
Authors: Deborah F van Breukelen-van der Stoep; Derkjen van Zeben; Boudewijn Klop; Gert-Jan M van de Geijn; Hans J W Janssen; Mieke J M W Hazes; Erwin Birnie; Noelle van der Meulen; Marijke A De Vries; Manuel Castro Cabezas Journal: PLoS One Date: 2015-10-20 Impact factor: 3.240